Buscar

Mostrando ítems 1-10 de 19

The International Network for Evaluating Outcomes (iNeo) of neonates: evolution, progress and opportunities

2019- Shah, P. S.; Lui, K.; Reichman, B.; Norman, M.; Kusuda, S.; [et al.]

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

2019- White, H. D.; Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; [et al.]

A Spanish Initiative to Know the Unmet Needs of Women with Lung Cancer:

2019- Campelo, R. G.; Vázquez Rivera, Francisca; Firvida Perez, Jose Luis; Lazaro Quintela, Martín; Vazquez, S.; [et al.]

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

2019- ARIAS RON, DAVID; LABANDEIRA GUERRA, CARMEN MARIA; Areses Manrique, María Carmen; SAMPEDRO DOMARCO, PAULA; Abdulkader Nallib, Ihab; [et al.]

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019- RUIZ BAÑOBRE, JUAN; Areses Manrique, María Carmen; Mosquera-Martinez, J.; Cortegoso Mosquera, Alexandra Sabela; Afonso-Afonso, F. J.; [et al.]

Indoor Radon and Lung Cancer Risk. A Pooling Study on the Second Risk Factor for Lung Cancer

2019- Ruano-Ravina, A.; Lorenzo-Gonzalez, M.; Provencio, M.; Torres Durán, María Luisa; Parente Lamelas, Isaura; [et al.]

Octogenarian women with acute coronary syndrome present frailty and readmissions more frequently than men

2019- Vicent, L.; Ariza-Solé, A.; Alegre, O.; Sanchís, J.; López Palop, Ramón; [et al.]

Biogeographical origin and timing of the founder ichthyosis TGM1 c.1187G > A mutation in an isolated Ecuadorian population

2019- Esperón Moldes, Uxía Saraiva; Pardo Seco, Jacobo José; Montalván-Suárez, M.; Fachal Vilar, Laura; Ginarte Val, Manuel Javier; [et al.]

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

2019- Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; Bregeault, M. F.; [et al.]

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

2019- Roe, M. T.; Li, Q. H.; Bhatt, D. L.; Bittner, V. A.; Diaz, R.; [et al.]

1
2